Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.4909 -0.0091 (-1.82%)
Streaming Delayed Price Updated: 10:54 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
From Sangamo Therapeutics, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.